From Name:
From Email:
To Name:
To Email:

Optional Message:

Supreme Court rules to speed marketing of lower-cost 'biosimilar' drugs

from The Hill

Manufacturers of copycat "biosimilar" medical products will be able to bring their drugs to the market faster after a unanimous U.S. Supreme Court decision Monday. The court in Sandoz v. Amgen ruled 9-0 in favor of generic drugmaker Sandoz in a dispute with rival company Amgen. The court ruled that manufacturers of low-cost biosimilars don't need to wait an extra six months after FDA approval to launch their product. The ruling is expected to save consumers — and the U.S. health system — billions of dollars. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063